As the second antibody-drug conjugate launched by Daiichi Sankyo and AstraZeneca, Datroway has a tough act to follow, coming on the heels of the companies’ emerging ADC cancer powerhouse Enhertu.

Daiichi Co. Ltd. (7643.TO) Japan Half-Year Ended March 31 PARENT 2025 2024 Revenue Y28.58 bln Y26.02 bln Operating Profit Y769.00 mln Y1.16 bln Pretax Profit Y762.00 mln Y1.16 bln Net Profit Y554 ...

Dai-ichi Life Holdings Inc. said on Monday that it plans to make an additional investment in UK-based Capula Investment Management, aiming to strengthen its ability to oversee non-traditional assets.

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

Dai-ichi Life Holdings (OTCPK:DCNSF) (OTCPK:DLICY) said on Monday that it plans to make an additional investment in UK-based Capula Investment Management, aiming to strengthen its ability to ...

Thank you for waiting. Now we would like to begin Daiichi Sankyo's Financial Results Conference on FY2024. I am Asakura from Corporate Communications. I am your moderator today. We will be using ...

Dai-Ichi Cutter Kogyo K.K. (1716.TO) Japan Nine Months Ended March 31 GROUP 2025 2024 Revenue Y15.20 bln Y15.54 bln Operating Profit Y1.38 bln Y1.88 bln Pretax Profit Y1.48 bln Y2.06 bln Net ...

The operator of the crippled Fukushima Daiichi nuclear power plant says the average daily increase of contaminated water in the year through March was the lowest since the 2011 accident. Tokyo ...

Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for Enhertu (trastuzumab deruxtecan) for the treatment of adult ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

TOKYO -- Dai-ichi Life Insurance and Nippon Life Insurance, two of Japan's biggest institutional investors, are navigating choppy waters churned up by the Trump administration's fast-changing ...